[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100344001":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":24,"responsibleParty":63,"collaborators":7,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":7,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":7,"enrollmentInfo":74,"targetDuration":77,"studyType":78,"phases":7,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Lund University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DIAGNOSTIC_TEST","Biopsies, blood","We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer",[14],"Targeted exon sequencing",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Karolina Holm, PhD","CONTACT","+46 730 84 17 61","karolina.holm@med.lu.se",{"name":22,"role":18,"phone":7,"phoneExt":7,"email":23},"Christel Reutersward, MSc","christel.reutersward@med.lu.se",[25,55],{"facility":5,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Lund","221 85","Sweden","SE",{"type":32,"coordinates":33},"Point",[34,35],13.19321,55.70584,{"lat":35,"lon":34},[38,40,44,47,49,51,53],{"name":17,"role":18,"phone":39,"phoneExt":7,"email":20},"+46 730 84 47 61",{"name":41,"role":18,"phone":42,"phoneExt":7,"email":43},"Ana Bosch Campos, MD, PhD","+46 46 17 76 03","ana.bosch_campos@med.lu.se",{"name":45,"role":46,"phone":7,"phoneExt":7,"email":7},"Åke Borg, Professor","PRINCIPAL_INVESTIGATOR",{"name":41,"role":48,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":50,"role":48,"phone":7,"phoneExt":7,"email":7},"Anna-Maria Larsson, MD, PhD",{"name":52,"role":48,"phone":7,"phoneExt":7,"email":7},"Lao Saal, Associated professor",{"name":54,"role":48,"phone":7,"phoneExt":7,"email":7},"Johan Staaf, Associated professor",{"facility":5,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},{"type":32,"coordinates":57},[34,35],{"lat":35,"lon":34},[60,62],{"name":61,"role":18,"phone":39,"phoneExt":7,"email":20},"Karolina Holm, MSc",{"name":45,"role":46,"phone":7,"phoneExt":7,"email":7},{"type":64,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100344001","sweden-cancerome-analysis-network---breast-recurrence-scan-b-rec-100344001",false,"NCT03758976","Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)","SCAN-B-rec: Infrastructure, Technology Platform and Clinical Research Development to Profile and Monitor Metastatic Breast Cancer","Inclusion Criteria:\n\n1. Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease.\n2. Age \\> 18 years.\n3. Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2.\n4. ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET).\n5. Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion.\n6. Signed informed consent according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\nUntreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.","ALL","18 Years",{"count":75,"type":76},2000,"ESTIMATED","10 Years","OBSERVATIONAL","Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure.\n\nThe main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response\u002Fresistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.",[81],"Metastatic Breast Cancer",[83,84,85,86],"Metastatic breast cancer","Molecular profiling","Circulating tumor DNA","Circulating tumor cells","2025-09-10",{"date":89,"type":90},"2025-09-16","ACTUAL",{"date":92,"type":90},"2019-01-21",{"date":94,"type":76},"2030-12-01",{"name":5,"class":6},2]